This is an Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC
≥ 18 and ≤ 75 years of age;
Have fully understood and voluntarily sign the ICF for this study (the icf must be signed before any trial-specific procedures are performed);Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure;
Histologically and/or cytologically documented metastatic colorectal adenocarcinoma;
Refractory to at least second line standard treatment containing fluorouracil, oxaliplatin and irinotecan;
Pregnant or lactating women;
Any factors that influence the usage of oral administration or any disease or condition that affects drug absorption;
Previous treatment with Tegafur Gimeracil Oteracil ;
Participated in clinical trials of other drugs within four weeks before enrollment;